Somatostatin in der pr�operativen therapie und postoperativen diagnostik eines patienten mit Verner-Morrison-Syndrom

Abstract

We report the case of a patient with Verner-Morrison syndrome due to a malignant MEN I-associated vipoma. Marked tumor-associated hypercalcemia could be treated successfully with somatostatin analogues prior to surgical therapy of the pancreatic tumor. Sixteen months after extirpation of the primary tumor recurrent tumor growth was diagnosed; at this time the patient was clinically asymptomatic and had no abnormal laboratory test results. Liver metastases and local metastases were identified using somatostatin receptor scintigraphy. We report and discuss the use of somatostatin in the treatment of tumor-associated symptoms in endocrine tumors and the possibility of identifying endocrine tumors by means of somatostatin receptor scintigraphy.

Biological Characterisation of [67Ga] or [68Ga] Labelled DFO-Octreotide (SDZ 216-927) for PET Studies of Somatostatin Receptor Positive Tumors

“…A very exiting new development is the use of new modified octreotide analogues which can be radiolabelled with gammaemitting isotopes such as [111In] or [ 123 I] for the scintigraphic in vivo localization of SRIF receptorpositive tumors in man (Kwekkeboom, Hoff, Lamberts, Oei and Krenning 1992;O'Connor, Kvols, Brown, Hung, Hayostek, Cho and Vetter 1992;Reubi, Waser, van Hagen, Lamberts, Krenning, Gebbers and Laissue 1992). Furthermore these new radiopharmaceuticals can guide prognostic and therapeutic decisions (Lamberts, Hofland, Koetsveld, Reubi, Bruining, Bakker and Krenning 1990;Pantev, Virgolini, Neuhold, Angelberger, Luger and Sinzinger 1991;Weinel, Neuhaus, Stapp, Klotter, Trautmann, Arnold, Josef and Rothemund 1992).…”